News|Articles|November 19, 2026

FDA Grants RMAT Designation to iSCIB1+ in Advanced Melanoma

Author(s)Matt Flowers
Fact checked by: Sabrina Serani
Listen
0:00 / 0:00

Key Takeaways

  • RMAT designation expands regulatory tools beyond fast track, including closer FDA interactions plus potential eligibility for rolling review, priority review, and accelerated approval if criteria are met.
  • A comprehensive FDA multidisciplinary meeting is planned to align phase 3 registrational design and manufacturing approach ahead of global execution.
SHOW MORE

iSCIB1+ advances toward a global phase 3 trial in advanced melanoma, with closer guidance from the FDA.

The FDA has granted regenerative medicine advanced therapy (RMAT) designation to iSCIB1+, an investigational DNA-based immunotherapy being developed by Scancell for patients with advanced melanoma. The designation provides additional regulatory support and opportunities to expedite development as the company prepares to advance the candidate into a global phase 3 registrational trial.1

The designation builds on the fast track designation previously granted to iSCIB1+ and provides Scancell with opportunities for more intensive engagement with the FDA, including guidance on the clinical development program and manufacturing strategy. RMAT designation incorporates benefits of breakthrough therapy and fast track designations, including eligibility for rolling review, priority review, and accelerated approval if applicable criteria are met.1,2

Scancell plans to request an initial comprehensive multidisciplinary meeting with the FDA to discuss the development program, including the design of the planned phase 3 trial and manufacturing strategy.

The global phase 3 registrational trial of iSCIB1+ remains on track to enroll its first patient in December 2026. The trial follows FDA clearance of the investigational new drug (IND)application and clinical trial authorization from the UK Medicines and Healthcare products Regulatory Agency earlier in 2026.

Phase 2 SCOPE Findings Support Further Development

The planned phase 3 study builds on findings from the ongoing phase 2 SCOPE trial (NCT04079166), which is evaluating SCIB1 and iSCIB1+ in combination with immune checkpoint inhibitors in patients with advanced melanoma. The investigational therapies are designed to stimulate tumor-directed immune responses through Scancell's DNA ImmunoBody platform.

In a news release announcing the update, Scancell reported survival findings from SCOPE based on a data cut analyzed November 12, 2026. At 24 months, overall survival (OS) was 82% across the combined SCIB1 and iSCIB1+ cohorts (n = 80). The iSCIB1+ cohort demonstrated a 24-month OS rate of 87%.1

Progression-free survival (PFS) findings were also reported. Among patients in the human leukocyte antigen (HLA)-targeted population, the 24-month PFS rate was 65% across the combined SCIB1 and iSCIB1+ cohorts. In the iSCIB1+ cohort alone, the 24-month PFS rate was 71%, with 1 patient experiencing disease progression. For historical context, the 24-month PFS rate reported with standard-of-care ipilimumab (Yervoy) plus nivolumab (Opdivo) in the phase 3 CheckMate 067 trial (NCT01844505) was 41.5%.

The complete response rate across the combined SCIB1 and iSCIB1+ cohorts increased to 28%, reaching 31% in cohort 3, which evaluated iSCIB1+.

Additional follow-up from SCOPE is anticipated in the first half of 2027, when Scancell expects to report more mature PFS findings and interim OS data.

iSCIB1+ Is Designed to Generate Tumor-Directed T-Cell Responses

iSCIB1+ is a DNA ImmunoBody therapy administered through needle-free intramuscular injection. The investigational vaccine encodes an antibody targeting the melanoma-associated antigens gp100 and TRP-2, with the goal of priming high-avidity T cells capable of recognizing and attacking tumor cells.

The candidate is being investigated in combination with checkpoint inhibitors, including ipilimumab and nivolumab, which are intended to enhance antitumor immune activity through complementary mechanisms. In the phase 2 SCOPE trial, the combination demonstrated a 77% PFS rate at 22 months in the target HLA population, with no increase in checkpoint inhibitor-related toxicities, according to Scancell.

“The FDA’s grant of RMAT designation for iSCIB1+, alongside fast track, recognizes its potential to address an unmet need in advanced melanoma and gives us closer engagement with the Agency as we start phase 3,” said Dr Phillip L’Huillier, CEO of Scancell, in the news release.

REFERENCES
1. Scancell provides corporate and clinical update. News release. Scancell. November 19, 2026. Accessed November 19, 2026. https://tinyurl.com/452dm9xp
2. Regenerative medicine advanced therapy designation. US Food and Drug Administration. Accessed November 19, 2026. https://tinyurl.com/sby2ppbt

Related to this article

FDA Removes PCNSL Limitation From Liso-Cel Label
The November 2026 prescribing information removes the limitation that previously excluded patients with primary or secondary central nervous system lymphoma from the therapy’s large B-cell lymphoma indications.